Akero Financial Statements From 2010 to 2025

AKRO Stock  USD 43.53  1.29  2.88%   
Akero Therapeutics financial statements provide useful quarterly and yearly information to potential Akero Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Akero Therapeutics financial statements helps investors assess Akero Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Akero Therapeutics' valuation are summarized below:
Market Capitalization
3.6 B
Earnings Share
(3.75)
We have found one hundred twenty available fundamental signals for Akero Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Akero Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 1.8 B. Also, Enterprise Value is likely to grow to about 1.4 B
Check Akero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Selling General Administrative of 19.9 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.61. Akero financial statements analysis is a perfect complement when working with Akero Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.

Akero Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets867.2 M825.9 M207.5 M
Slightly volatile
Other Current Liabilities31.6 M30.1 M7.6 M
Slightly volatile
Total Current Liabilities41.7 M39.8 M10.7 M
Slightly volatile
Accounts PayableMM2.6 M
Slightly volatile
Cash189.1 M340.2 M98 M
Slightly volatile
Non Current Assets Total58.3 M55.5 M8.7 M
Slightly volatile
Other Assets1.091.1560.9 K
Pretty Stable
Cash And Short Term Investments780.2 M743.1 M193.7 M
Slightly volatile
Common Stock Shares Outstanding39.5 M67.1 M31.9 M
Slightly volatile
Liabilities And Stockholders Equity867.2 M825.9 M207.5 M
Slightly volatile
Non Current Liabilities Total20.5 M36 M16.3 M
Pretty Stable
Other Current Assets28.7 M27.3 M5.8 M
Slightly volatile
Total Liabilities45.9 M75.8 M26 M
Slightly volatile
Total Current Assets808.9 M770.4 M198.7 M
Slightly volatile
Net Working Capital767.2 M730.6 M188 M
Slightly volatile
Capital Surpluse438.3 M861.2 M270.9 M
Slightly volatile
Non Current Liabilities Other270 K194 K249.1 K
Slightly volatile
Short and Long Term Debt Total502.6 K529 K3.7 M
Slightly volatile
Property Plant And Equipment NetM755 K1.6 M
Slightly volatile
Net Receivables339.9 K479.6 K267.6 K
Slightly volatile
Capital Lease Obligations1.2 M1.2 M1.7 M
Slightly volatile
Property Plant And Equipment Gross792.5 K755 K1.5 M
Slightly volatile
Long Term Debt Total7.6 M8.6 M9.4 M
Slightly volatile

Akero Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative19.9 M37.9 M10.8 M
Slightly volatile
Research Development259.9 M247.5 M60 M
Slightly volatile
Total Operating Expenses299.7 M285.4 M72.1 M
Slightly volatile
Interest Income20.5 M38 M40.4 M
Slightly volatile
Reconciled Depreciation25 K18 K21.9 K
Slightly volatile
Non Operating Income Net Other4.7 M4.5 M1.7 M
Slightly volatile
Selling And Marketing Expenses23.2 K26.1 K28.5 K
Slightly volatile

Akero Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock440.8 K464 KM
Very volatile
Other Cashflows From Financing Activities10.7 M12.8 M7.3 M
Pretty Stable
Total Cash From Financing Activities468.1 M445.8 M121.7 M
Slightly volatile
End Period Cash Flow179.3 M340.2 M93 M
Slightly volatile
Change To Netincome25.8 M21.2 M49.8 M
Slightly volatile
Stock Based Compensation31.2 M29.7 M7.8 M
Slightly volatile
Issuance Of Capital Stock221.3 M423.1 M144.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation6.977.848.5433
Slightly volatile
Payables Turnover0.00450.00470.0479
Slightly volatile
Cash Per Share6.1911.06814.2638
Slightly volatile
Days Payables Outstanding83.7 K79.7 K21.1 K
Slightly volatile
Income Quality0.620.91290.8471
Slightly volatile
Net Debt To EBITDA2.11.19022.2097
Slightly volatile
Current Ratio14.6219.378711.309
Slightly volatile
Debt To Equity7.0E-47.0E-40.0106
Slightly volatile
Capex Per Share0.00510.00540.1346
Slightly volatile
Debt To Assets6.0E-46.0E-40.0099
Slightly volatile
Days Of Payables Outstanding83.7 K79.7 K21.1 K
Slightly volatile
Ebt Per Ebit0.840.88313.7435
Slightly volatile
Long Term Debt To Capitalization7.0E-47.0E-40.0091
Slightly volatile
Total Debt To Capitalization7.0E-47.0E-40.0104
Slightly volatile
Debt Equity Ratio7.0E-47.0E-40.0106
Slightly volatile
Quick Ratio14.6219.378711.309
Slightly volatile
Net Income Per E B T1.091.121.0095
Slightly volatile
Cash Ratio14.288.55868.5619
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.691.151.6613
Slightly volatile
Debt Ratio6.0E-46.0E-40.0099
Slightly volatile

Akero Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B869.2 M
Slightly volatile
Enterprise Value1.4 B1.4 B759.4 M
Slightly volatile

Akero Fundamental Market Drivers

Cash And Short Term Investments743.1 M

Akero Upcoming Events

15th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Akero Therapeutics Financial Statements

Akero Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Akero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue33.4 K31.7 K

Pair Trading with Akero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Akero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Akero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Akero Stock

  0.68DMAC DiaMedica TherapeuticsPairCorr
  0.78VALN Valneva SE ADRPairCorr

Moving against Akero Stock

  0.8VINC Vincerx PharmaPairCorr
  0.65VKTX Viking TherapeuticsPairCorr
  0.61ME 23Andme HoldingPairCorr
  0.53VANI Vivani Medical Earnings Call This WeekPairCorr
  0.53DSGN Design TherapeuticsPairCorr
The ability to find closely correlated positions to Akero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Akero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Akero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Akero Therapeutics to buy it.
The correlation of Akero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Akero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Akero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Akero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Akero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akero Therapeutics Stock:
Check out the analysis of Akero Therapeutics Correlation against competitors.
To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.75)
Return On Assets
(0.25)
Return On Equity
(0.39)
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.